← American Oncology Network, Inc. (AONCW) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
American Oncology Network, Inc. (AONCW)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
11
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Taxoprexin | Phase 2 | Metastatic Melanoma |
| Standard Medical Care (SMC) | Phase 3 | Anemia |
| Ferric Carboxymaltose | Phase 3 | Heart Failure |
| Injectafer | Phase 3 | Cancer and Chemotherapy Related Anemia |
| Ferric Carboxymaltose (FCM) | Phase 3 | Iron Deficiency Anemia |
| Venofer | Phase 3 | Anemia |
| Ferrous Sulfate tablets | Phase 3 | Postpartum Anemia |
| Zoledronic Acid | Phase 3 | Giant Cell Tumor of Bone |
| tamoxifen citrate | Phase 3 | Breast Cancer |
| Exemestane | Phase 3 | Breast Adenocarcinoma |
| horse anti-thymocyte globulin (ATG) | Phase 3 | Severe Aplastic Anemia |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AONCW (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.